NSRX
Nasus Pharma Ltd.
NYSE MKT: NSRX · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$2.75
+1.85% today
Updated 2026-05-01
Market cap
$37.24M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.72
Dividend yield
—
52W range
$0 – $10
Volume
0.2M
Nasus Pharma Ltd. (NSRX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | $-1.21M | $-1.03M | $-665000.00 | $-4.92M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $14000.00 |
| Depreciation | — | — | — | — |
| Stock-based comp | $23000.00 | $39000.00 | $10000.00 | $447000.00 |
| Free cash flow | $-1.21M | $-1.03M | $-665000.00 | $-4.93M |
| Investing cash flow | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Share repurchases | — | — | — | — |
| Debt repayment | — | — | — | — |
| Net change in cash | — | — | — | — |